Nevada § 439B.640 Manufacturer of drug that has undergone significant price increase to submit report describing reasons for increase; affirmation of accuracy of report; contents of report

Nevada Statutes

§ 439B.640 — Manufacturer of drug that has undergone significant price increase to submit report describing reasons for increase; affirmation of accuracy of report; contents of report

Nevada § 439B.640

Title 40PUBLIC HEALTH AND SAFETY

Ch. 439BRestraining

REPORTING OF CERTAIN INFORMATION RELATING TO PRESCRIPTION DRUGS

This text of Nevada § 439B.640 (Manufacturer of drug that has undergone significant price increase to submit report describing reasons for increase; affirmation of accuracy of report; contents of report) is published on Counsel Stack Legal Research, covering Nevada primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Nev. Rev. Stat. § 439B.640 (2026).

Text

1. On or before April 1 of a year in which a drug is included on either or both of the lists compiled pursuant to paragraph (b) or (c) of subsection 1 of NRS 439B.630 , the manufacturer of the drug shall submit to the Department:

(a)A report describing the reasons for the increase in the wholesale acquisition cost of the drug described in paragraph (b) or (c), as applicable, of subsection 1 of NRS 439B.630 ; and

(b)A statement signed by the person responsible for compiling the report under penalty of perjury affirming the accuracy of the information in the report. 2. The report submitted pursuant to paragraph (a) of subsection 1 must include, without limitation:

(a)A list of each factor that has contributed to the increase;

(b)The percentage of the total increase that is attributable t

Free access — add to your briefcase to read the full text and ask questions with AI

1. On or before April 1 of a year in which a drug is included on either or both of the lists compiled pursuant to paragraph (b) or (c) of subsection 1 of NRS 439B.630 , the manufacturer of the drug shall submit to the Department:
(a) A report describing the reasons for the increase in the wholesale acquisition cost of the drug described in paragraph (b) or (c), as applicable, of subsection 1 of NRS 439B.630 ; and
(b) A statement signed by the person responsible for compiling the report under penalty of perjury affirming the accuracy of the information in the report.
2. The report submitted pursuant to paragraph (a) of subsection 1 must include, without limitation:
(a) A list of each factor that has contributed to the increase;
(b) The percentage of the total increase that is attributable to each factor;
(c) An explanation of the role of each factor in the increase; and
(d) Any other information prescribed by regulation by the Department.